Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Single Arm Phase 1b Study Of Avelumab Plus Axitinib As First Line Treatment In Patients With Advanced Hepatocellular Carcinoma

X
Trial Profile

An Open Label, Single Arm Phase 1b Study Of Avelumab Plus Axitinib As First Line Treatment In Patients With Advanced Hepatocellular Carcinoma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary) ; Axitinib (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Acronyms VEGF Liver 100
  • Sponsors Pfizer
  • Most Recent Events

    • 14 Nov 2019 Status changed from active, no longer recruiting to completed.
    • 06 Jul 2019 Planned End Date changed from 7 Oct 2019 to 14 Jan 2020.
    • 06 Jul 2019 Planned primary completion date changed from 13 Aug 2019 to 15 Aug 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top